CL2021002070A1 - Pharmaceutical compositions comprising meloxicam. - Google Patents
Pharmaceutical compositions comprising meloxicam.Info
- Publication number
- CL2021002070A1 CL2021002070A1 CL2021002070A CL2021002070A CL2021002070A1 CL 2021002070 A1 CL2021002070 A1 CL 2021002070A1 CL 2021002070 A CL2021002070 A CL 2021002070A CL 2021002070 A CL2021002070 A CL 2021002070A CL 2021002070 A1 CL2021002070 A1 CL 2021002070A1
- Authority
- CL
- Chile
- Prior art keywords
- meloxicam
- migraine
- rizatriptan
- pain
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Se describe en la presente composiciones que comprenden un NSAID como meloxicam y/o rizatriptán en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden ser oralmente administradas, por ejemplo, para mejorar la biodisponibilidad o farmacocinéticas del NSAID para el tratamiento de dolor como migraña, artritis, y otras afecciones. También se describen aquí métodos para tratar el dolor, como migraña, que comprenden administrar meloxicam y rizatriptán a un ser humano que sufre de dolor, como migraña. Para la migraña, estos métodos pueden ser particularmente útiles cuando el meloxicam y el rizatriptán son administrados mientras el ser humano está sufriendo de un ataque agudo de dolor de migraña o aura de migraña. En algunas modalidades, la combinación de meloxicam y rizatriptán pueden ser administrados en una forma que resulta en una Tmáx de meloxicam de 3 horas o menos.Described herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions can be administered orally, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human suffering from pain, such as migraine. For migraine, these methods may be particularly useful when meloxicam and rizatriptan are administered while the human is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan can be administered in a manner that results in a meloxicam Tmax of 3 hours or less.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802198P | 2019-02-06 | 2019-02-06 | |
| US201962803756P | 2019-02-11 | 2019-02-11 | |
| US201962835613P | 2019-04-18 | 2019-04-18 | |
| US201962846311P | 2019-05-10 | 2019-05-10 | |
| US201962860705P | 2019-06-12 | 2019-06-12 | |
| US201962895956P | 2019-09-04 | 2019-09-04 | |
| US201962895933P | 2019-09-04 | 2019-09-04 | |
| US201962955905P | 2019-12-31 | 2019-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002070A1 true CL2021002070A1 (en) | 2022-04-01 |
Family
ID=71947112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002070A CL2021002070A1 (en) | 2019-02-06 | 2021-08-05 | Pharmaceutical compositions comprising meloxicam. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3920909A4 (en) |
| JP (3) | JP7237386B2 (en) |
| KR (1) | KR20210118880A (en) |
| CN (1) | CN113423397A (en) |
| AU (2) | AU2020218253B2 (en) |
| BR (1) | BR112021015467A2 (en) |
| CA (2) | CA3213549A1 (en) |
| CL (1) | CL2021002070A1 (en) |
| CO (1) | CO2021010380A2 (en) |
| CR (1) | CR20210420A (en) |
| EC (1) | ECSP21060962A (en) |
| IL (1) | IL285389A (en) |
| MA (1) | MA54904A (en) |
| MX (1) | MX2021009435A (en) |
| PE (1) | PE20212157A1 (en) |
| SG (1) | SG11202107926XA (en) |
| WO (1) | WO2020163620A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024502041A (en) * | 2020-12-31 | 2024-01-17 | アクスサム セラピューティクス インコーポレイテッド | Pharmaceutical compositions containing meloxicam |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1126841B1 (en) * | 1998-11-02 | 2004-12-15 | Merck & Co., Inc. | Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine |
| US20040214861A1 (en) * | 2003-03-28 | 2004-10-28 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US20090068262A1 (en) * | 2007-04-04 | 2009-03-12 | Ilan Zalit | Rapid dissolution of combination products |
| ES2769949T3 (en) * | 2009-05-13 | 2020-06-29 | Cydex Pharmaceuticals Inc | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of preparing and using them |
| US9821075B2 (en) * | 2015-02-10 | 2017-11-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| AU2016218992C1 (en) * | 2015-02-10 | 2019-09-26 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| SI3256138T1 (en) * | 2015-11-25 | 2022-07-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| CN109952314A (en) * | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | Treat intractable migraine |
| PT3565550T (en) * | 2017-01-04 | 2021-01-20 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
| US10471014B2 (en) * | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| CN110612103B (en) * | 2017-05-10 | 2023-08-22 | 艾克萨姆治疗公司 | Pharmaceutical composition comprising meloxicam |
-
2020
- 2020-02-06 KR KR1020217026519A patent/KR20210118880A/en not_active Application Discontinuation
- 2020-02-06 SG SG11202107926XA patent/SG11202107926XA/en unknown
- 2020-02-06 EP EP20752178.2A patent/EP3920909A4/en active Pending
- 2020-02-06 CR CR20210420A patent/CR20210420A/en unknown
- 2020-02-06 PE PE2021001288A patent/PE20212157A1/en unknown
- 2020-02-06 WO PCT/US2020/017046 patent/WO2020163620A1/en unknown
- 2020-02-06 JP JP2021545919A patent/JP7237386B2/en active Active
- 2020-02-06 CN CN202080012487.9A patent/CN113423397A/en active Pending
- 2020-02-06 MX MX2021009435A patent/MX2021009435A/en unknown
- 2020-02-06 BR BR112021015467-1A patent/BR112021015467A2/en unknown
- 2020-02-06 CA CA3213549A patent/CA3213549A1/en active Pending
- 2020-02-06 CA CA3128940A patent/CA3128940C/en active Active
- 2020-02-06 MA MA054904A patent/MA54904A/en unknown
- 2020-02-06 AU AU2020218253A patent/AU2020218253B2/en active Active
-
2021
- 2021-08-04 IL IL285389A patent/IL285389A/en unknown
- 2021-08-05 CL CL2021002070A patent/CL2021002070A1/en unknown
- 2021-08-06 CO CONC2021/0010380A patent/CO2021010380A2/en unknown
- 2021-08-17 EC ECSENADI202160962A patent/ECSP21060962A/en unknown
-
2023
- 2023-02-21 JP JP2023025218A patent/JP7420990B2/en active Active
- 2023-04-27 AU AU2023202545A patent/AU2023202545A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002855A patent/JP2024026732A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021009435A (en) | 2021-09-10 |
| EP3920909A4 (en) | 2022-11-30 |
| MA54904A (en) | 2021-12-15 |
| WO2020163620A1 (en) | 2020-08-13 |
| ECSP21060962A (en) | 2021-11-30 |
| CO2021010380A2 (en) | 2021-09-30 |
| EP3920909A1 (en) | 2021-12-15 |
| JP2023062144A (en) | 2023-05-02 |
| JP2022519670A (en) | 2022-03-24 |
| AU2020218253A1 (en) | 2021-08-12 |
| CA3128940A1 (en) | 2020-08-13 |
| SG11202107926XA (en) | 2021-08-30 |
| CR20210420A (en) | 2021-12-22 |
| JP2024026732A (en) | 2024-02-28 |
| AU2020218253B2 (en) | 2023-02-23 |
| JP7237386B2 (en) | 2023-03-13 |
| IL285389A (en) | 2021-09-30 |
| CN113423397A (en) | 2021-09-21 |
| BR112021015467A2 (en) | 2021-10-05 |
| JP7420990B2 (en) | 2024-01-23 |
| AU2023202545A1 (en) | 2023-05-18 |
| CA3128940C (en) | 2023-11-07 |
| PE20212157A1 (en) | 2021-11-09 |
| KR20210118880A (en) | 2021-10-01 |
| CA3213549A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017149726A5 (en) | ||
| CR20210061A (en) | Pharmaceutical compositions comprising meloxicam | |
| CL2018001420A1 (en) | Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853) | |
| EA201691454A1 (en) | COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING | |
| CL2018001677A1 (en) | Treatment of fabry disease in patients not treated and previously treated with ert | |
| CO6531463A2 (en) | COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR | |
| CO6341486A2 (en) | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | |
| EA200701195A1 (en) | CONTAINING CEFALOSPORIN COMPOSITIONS WITH NANOPARTICLES AND WITH CONTROLLED DELIVERY | |
| CL2020002512A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors. | |
| MX2022003072A (en) | Use of pridopidine for treating functional decline. | |
| BR112015023439A2 (en) | combination of cancer treatments using micro-ovens and egfr-tki inhibitors | |
| EA201290833A1 (en) | APPLICATION OF AMISULPRIDE AS ANTI-TRAFFIC MEANS | |
| CL2008003201A1 (en) | Pharmaceutical composition comprising 0.5 to 50 mg of gaboxadol or a pharmaceutically acceptable salt thereof, and one or more inhibitors of pat1 and / or one or more inhibitors of oat, wherein said composition provides an in vivo plasma profile with a tmax longer than 20 minutes, useful in sleep disorders treatments. | |
| BR112015018360A2 (en) | Combination therapy for the treatment of nosocomial pneumonia | |
| CL2019000190A1 (en) | Treatment and prevention of sleep disorders. | |
| EA201692392A1 (en) | NEW MEDICINE FORM OF MELOXYCAM | |
| ECSP21060962A (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | |
| ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MX2010010334A (en) | Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsu lfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide. | |
| MX2021002322A (en) | Novel methods. | |
| CO2020004034A2 (en) | Methods for the treatment of muscular dystrophy | |
| CL2020003010A1 (en) | Modulators of apol1 expression | |
| BR112014030777A2 (en) | Method and composition to relieve tumor symptoms | |
| CO2021014024A2 (en) | Methods for treating muscular dystrophy with casimersin | |
| BR112019005224A2 (en) | dosage form for prolonged relief |